



BEST AVAILABLE COPY

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

**(use as many sheets as necessary)**

Sheet

1

91

**2**

**Complete if Known**

Application Number

10/631.967

Filing Date

**1 August 2003**

First Named Inventor

Alexander HILLISCH et al.

### Group Art Unit

1614

**Examiner Name**

Unknown

Attorney Docket Number

**GULDE-0002**

## U.S. PATENT DOCUMENTS

[illegible]

## FOREIGN PATENT DOCUMENTS

[illegible]

**Examiner  
Signature**

Date Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 If possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached. Number refers to English language corresponding family member.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

BEST AVAILABLE COPY

Please type a plus sign (+) inside this box →



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application Number	10/631,967
		Filing Date	1 August 2003
		First Named Inventor	Alexander HILLISCH et al.
		Group Art Unit	1614
		Examiner Name	Unknown
		Attorney Docket Number	GULDE-0002
Sheet	2	of	2

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T 2
BB	5	D. LOUTRADIS ET AL., "Preovulatory effects of the progesterone antagonist mifepristone (RU486) in mice," Human Reproduction, 1991, vol. 6, no.9, pages 1238-1240.	
	6	K. CHWALISZ ET AL., "Antiproliferative effects of progesterone antagonists and progesterone receptor modulators on the endometrium," Steroids, 2000, vol. 65, pages 741-751.	
	7	O.D. SLAYDEN ET AL., "Reversible suppression of menstruation with progesterone antagonists in rhesus macaques," Human Reproduction, 2001, vol. 16, no. 8, pages 1562-1574.	
	8	W. ELGER ET AL., "Endocrine pharmacological characterization of progesterone antagonists and progesterone receptor modulators with respect to PR-agonistic and antagonistic activity," Steroids, 2000, vol. 65, pages 713-723.	
	9	W. ELGER ET AL., "Sulfamates of various estrogens are prodrugs with increased systemic and reduced hepatic estrogenicity at oral application," J. Steroid Biochem. Molec. Biol., 1995, vol. 55, no. 3/4, pages 395-403.	
	10	E. M. COUTINHO ET AL., "Is Menstruation Obsolete?" 1999, New York, Oxford University Press.	
	11	E.ISAKSSON ET AL., "Effects of oral contraceptives on breast epithelial proliferation," Breast Cancer Research and Treatment, 2001, vol. 65, pages 163-169.	
BB	12	A. J. SPIEGEL ET AL., "Use of nonaqueous solvents in parenteral products," Journal of Pharmaceutical Sciences, October 1963, vol. 52, no.10, pages 917-927.	
	13	Von-Professor Dr. H. v. Czetsch-Lindenwald, "Pentaerythritester als pharmazeutische Hilfsstoffe," Pharmazeutische Technologie, 1961, Jahrg. 23, p. 72-74.	English translation needed
	14	Arzneimittel, Synthetische s. Chemotherapie und Pharmakotherapeutica, Arzneimittelzubereitung, pages 1-40	
BB	15	LOUIS J. RAVIN, "Preformulation," Bioavailability and Bioequivalency Testing, Chapter 75, pages 1355-1497 <span style="border: 1px solid black; padding: 2px;">date missing</span>	
BB	16	DWIGHT L. DEARDORFF, "Ophtalmic Preparations," Medicated Applications, Chapter 86, pages 1498-1628. <span style="border: 1px solid black; padding: 2px;">date missing</span>	
	17	ROUSSET-UCLEF, "Nouveau medicament notmment pour le traitement des troubles dus-a une insuffisance de secretion de corps jaune," Bulletin officiel de la Propriete Industrielle, no. 30 du 24 juillet 1967. <i>English translation needed</i>	
BB	18	G. TEUTSCH ET AL., "11Beta-substituted steroids, an original pathway to antihormones, 1988, vol. 31, no. 4B, pages 549-565.	
BB	19	XIANG-SHU FEI ET AL., "New, convenient route four trifluoromethylation of steroidal molecules," J. Chem. Soc., Perkin Trans. 1, 1998, pages 1139-1142.	

Examiner Signature	<i>Radio</i>	Date Considered	8/3/05
-----------------------	--------------	--------------------	--------